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Objective: To evaluate the efﬁcacy of probiotics in the prevention of
gastrointestinal colonization by Candida species, of late-onset sepsis and
neurological outcome in preterm newborns.
Study Design: A prospective study was conducted in 249 preterms who
were subdivided into three groups: one group (n¼83) was supplemented
with Lactobacillus (L.) reuteri, one group with L. rhamnosus (n¼83)
and the other with no supplementation (n¼83). The fungal
colonization in the gastrointestinal tract, the late onset of sepsis and
clinical parameters were recorded. A neurological structured assessment
was further performed at 1 year of age.
Result: Candida stool colonization was signiﬁcantly higher (P<0.01) in
the control group than in the groups treated with probiotics. The
L. reuteri group presented a signiﬁcantly higher reduction in
gastrointestinal symptoms than did the L. rhamnosus and control
groups. Infants treated with probiotics showed a statistically signiﬁcant
lower incidence of abnormal neurological outcome than did the control
group.
Conclusion: The use of both probiotics seems to be effective in the
prevention of gastrointestinal colonization by Candida, in the protection from
late-onset sepis and in reducing abnormal neurological outcomes in preterms.
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Introduction
The incidence of Candidemia in the neonatal intensive care unit
(NICU) is steadily increasing, with an estimated incidence of 1.6 to
9% in very-low-birth-weight infants and of 15% in extremely low-
birth-weight infants.
1–4 Low birth weight is an important risk
factor in neonatal mortality and in various morbidities, because of
the immaturity of both the immune system and the barrier
functions of the gastrointestinal tract, as well as the invasive
diagnostic and therapeutic procedures.
1 In a report of the National
Nosocomial Infections Surveillance System, Candida species were
ranked second in frequency among blood culture isolates obtained
from neonates in high-risk nurseries.
2–4 Colonization by Candida
species is also frequently associated with an increased risk for
invasive fungal infections (IFI),
5,6 and it can always be found
preliminarily to the development of IFI thanks to a careful
investigation. The gastrointestinal tract seems to be the site most
frequently implicated in systemic dissemination, as the incidence of
rectal fungal colonization from several single-site studies of very-
low-birth-weight infants is between 19.2 and 45% and it is higher
(63%) when stool is cultured directly.
7
Premature newborns in the intensive care setting harbor a
bacterial ﬂora that is greatly modiﬁed, composed of <20 species,
with predominant aerobes such as Staphylococci (coagulase
negative and Staphylococcus aureus), enterobacteria (Klebsiella)
and enterococci, whereas the predominant anaerobes include
Clostridia.
8
A normal bacterial ﬂora inhibits Candida growth by competing
for both adhesion sites and nutrients.
9 Antibiotic therapy and
infective events induce rapid changes in the intestinal microﬂora,
whereas hygienic conditions and nutrition induce slow changes.
The use of H2 blockers is considered a further risk factor for
Candida infection.
10 The direct introduction of particular
microbiological strains into the diet, in particular those known as
‘probiotics,’ can positively inﬂuence the intestinal microbial
population.
11 The bacteria most frequently used as probiotics are
the biﬁdobacteria and certain strains of lactobacilli, including
Lactobacillus (L.) reuteri and L. rhamnosus. Several trials have
reported the beneﬁcial effects of the use of these probiotics in
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www.nature.com/jpreducing undesirable outcomes such as diarrhea, colon distension
and abdominal cramps, but few clinical trials exist for preterm
infants. Early comparative studies have reported data on the
safety and potential colonization of probiotics in infants and
on the impact of probiotic supplementation on their enteric
microﬂora.
12–17
Therefore, the purposes of this were as follows: (1) to evaluate
the hypothesis that supplementation with probiotics may reduce the
colonization and expansion of fungal colonies in the
gastrointestinal tract, and reduce the risk of bacterial and/or fungal
nosocomial infections in the NICU; (2) to determine a possible
difference according to birth weight; as newborns with candidiasis
have reported a worse neuronal development than the control
group:
18 a further objective of this study was (3) to examine the
effect of probiotic supplementation on clinical neurological
outcomes in NICU newborns.
Methods
From January 2004 to December 2007, a prospective randomized
trial was conducted in 249 preterms with a birth weight <2500g
and a gestational age <37 weeks consecutively admitted at the
NICU of the Policlinico University of Catania (Italy), which is a
level III neonatal center. All the infants were outborn. Inclusion
criteria were admission to the NICU, a stable oral feeding within
72h of birth and an informed parental consent; exclusion criteria
were the presence of major congenital malformation or antenatal
and perinatal risk factors for sepsis.
The newborns were randomized into three groups by a random
number table: group I (n¼83; 12 with a birth weight <1500g,
71 X1500g) received supplementation with L. reuteri American
Type Culture Collection (ATCC) 55730 5 drops daily; group II
(n¼83; 28 <1500g, 55 X1500g) received supplementation with
L. rhamnosus ATCC 53103 1 capsule daily; and group III included
newborns with no probiotics (control; n¼83; 16 <1500g, 67
X1500g). Patients received supplementation from the ﬁrst 72h
after hospitalization for 6 weeks or until they were discharged from
the NICU.
Clinical procedures
The nutritional policy was conducted as an enteral feeding
with breast milk or formula milk (1ml every 3h) through an
orogastric tube within few hours after delivery. After the ﬁrst day of
life, parenteral nutrition was provided through a Premicath
catheter; glucose, amino acids and lipids were administered from
the second day of life. Nutrition administered through oral access
with intermittent meals or continuous pump feeding was
progressively increased, if tolerated, and parenteral nutrition was
progressively decreased and stopped, following the same protocols
during the study period, as reported by the international
guidelines.
19,20
Infants were weighed daily, and the day on which parenteral
nutritional was stopped was also recorded. All infants were carefully
examined by the nurses at least twice daily for gastrointestinal
symptoms,
21 such as regurgitation (deﬁned as the passage of
reﬂuxed gastric contents into the oral pharynx), vomiting (deﬁned
as the expulsion of the reﬂuxed gastric contents from the mouth,
that is, feeding intolerance), abdominal distension and
characteristics of the feces. A hydrolyzed formula was used when
newborns presented any gastrointestinal symptoms to improve the
feeding tolerance. Length of hospitalization was also recorded.
Clinical signs of infection were monitored, including fever,
desaturation crisis, apnea, bradycardia, pallor or grayish coloring,
necessity of O2 supplementation and/or reintubation. The following
laboratory parameters were also monitored cultures of organic
liquids, C-reactive protein and blood count. Investigations to detect
any mycotic involvement of the organs included ultrasounds (USs)
(renal, cardiac, abdominal, transfontanellar), examination of the
fundus oculi and chest X-rays.
Microbiology
Stool samples and gastric aspirate specimens were collected in
sterile containers. Oropharyngeal specimens were collected on
swabs and immediately transported to the laboratory situated in the
same structure for processing.
Gastric aspirations and pharyngeal swabs were cultured for
Candida detection at birth and after 7, 14, 21 and 28 days;
quantitative fungal stool cultures were also examined at the same
time.
22 Infants were considered at high level of colonization if they
presented >10
4CFU (colony-forming unit) per gram of feces.
7
Blood cultures and Platelia Candida test were conducted for the
diagnosis of invasive candidiasis and to evaluate antifungal
chemotherapy efﬁcacy.
23
Proven fungal or bacterial infection was deﬁned as a positive
culture: (1) from blood (drawn from peripheral sites); (2) from
urine (collected by suprapubic sterile puncture or sterile bladder
catheterization, with a growth of 10000 fungal organisms per ml);
(3) from cerebrospinal ﬂuid; or (4) from intravascular catheter tip
(only considered proof of microbiologically documented fungal
infection in patients with previous peripheral colonization by the
same species). During the study period, infection-control policies
did not signiﬁcantly differ in our Unit following the same criteria
expressed by previously published protocols.
24
Treatment
L. reuteri (ATCC 55730) was administered at the dose of 5 drops
per day in an oil formulation, which delivered 1 10
8CFU,
through an orogastric tube or into the mouth directly.
17,25
L. rhamnosus (ATCC 53103) was administered at the dose of
1 capsule per day, equivalent to 6 10
9CFU. The capsules were
opened and contents dispersed in water before administering.
Probiotics treatment continued until infants left the NICU.
26
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Journal of PerinatologyAntimycotic treatment consisted of liposomal Amphotericin B at
the initial dose of 1mgkg
 1 per day, with a gradual increase up to
a maximum of 6mgkg
 1 per day, by continuous infusions over
30min.
27 Treatment was stopped 7 days after a negative culture for
Candida and three consecutive negative C-reactive protein and
Candida antigen tests.
Antibiotic treatment was carried out after antibiotic assay with
the following drugs: Teicoplanin, Vancocin, Ampicillin sulbactam,
Amikacin, Imipenem, Meropenem. Treatment was stopped 7 to 12
days after negative assay of C-reactive protein and the absence of
clinical signs of infection.
28
Neurological assessment
The HINE (Hammersmith Infant Neurological examination) was
conducted to assess the neurological status of all newborns at a
corrected age of 12 months.
29 This is a structured neurological
examination, including the assessment of cranial nerve, posture,
movements, tone and reﬂexes. An optimality score is obtained by
calculating the distribution of the score frequency in the
normal population, deﬁning as optimal all the scores
found in at least 90% of the cohort. At 12 months, the scores equal
to or above 73 were regarded as optimal, and those below 73 as
suboptimal.
29
Cranial US was performed for each preterm infant in the ﬁrst
week of life and another between 15 and 21 days after birth and at
least one at term age. An US scan was considered as abnormal if
one of the following abnormalities was detected: echodensities
persisting for more than 14 days without cyst formation, cystic
periventricular leukomalacia, periventricular parenchymal
hemorrhagic involvement and isolated ventricular dilatation.
30
Ethics
Ethical approval was obtained from the ethics committee of our
institution.
Statistical methods
The primary end point was to evaluate the incidence of enteric
fungal colonization. The w
2 test was used to analyze the data along
with Fisher’s exact test when applicable. The anthropometric
variables (weight at birth and gestational age) were reported as
means±s.d. The intergroup comparisons (L. reuteri,
L. rhamnosus, control) for all variables were performed by a
nonparametric test (Kruskall–Wallis with a post hoc test of Dunn).
The same analysis was carried out for the total population and for
the newborns divided according to the birth weight, both <1500
and X1500g. The level of signiﬁcance was set at P<0.05.
Results
The demographic characteristics of preterm infants are reported in
Table 1, with a similar distribution in the three groups for all
parameters. No signiﬁcant differences at baseline between the three
groups were seen for the presence of major risk factor (maternal
antenatal steroid). In our study, we did not use postnatal steroid.
The group supplemented with L. reuteri presented a signiﬁcant
reduction in gastrointestinal symptoms (Table 2) than the
L. rhamnosus and control group. Furthermore, the control group
fed a higher percentage of hydrolyzed formula milk (Table 2) than
both the probiotic groups.
The duration of parenteral nutrition (Table 2, Figure 1) was
statistically different between L. reuteri and both L. rhamnosus
and control group (P<0.0001), whereas there was not any
statistically difference between the L. rhamnosus and the control
groups. Similarly, the energy quotient (kcalkg
 1) was quickly
achieved in the L. reuteri group compared with the control and the
L. rhamnosus group (P<0.0001) (Table 2, Figure 1)
Candida stool colonization was signiﬁcantly higher (P<0.01)
in the control group than in both probiotic groups (Table 2).
Table 1 Demographic characteristics of the preterm infants
Parameters L. reuteri L. rhamnosus Controls P-value (<0.05)
No. of newborns 83 83 83
Gestational age (weeks) 33.8±1.8 33.3±1.6 33.3±2.1 NS
Birth weight (grams) 1998.7±439 1940.7±590 1945.7±465 NS
Male/female 44/39 45/38 46/37 NS
Cesarean sections % 94 86 93 NS
Assisted ventilation mean days±s.d. 1.3±5.6 2.9±6.3 3.1±6.0 NS
Central venous catheter % 48 52 48 NS
Respiratory distress syndrome % of neonates 36.1 51.8 43.3 NS
Maternal antenatal steroid 42 43 40 NS
H2 blockers received mean days±s.d. 10.8±11.9 9.6±12 11.7±12.6 NS
Time of initiation of probiotic Mean days±s.d. 1.42±0.49 1.40±0.49 F NS
Abnormal Cerebral scan % 16 13 19 NS
Abbreviations: L. reuteri, Lactobacillus reuteri; L. rhamnosus; Lactobacillus rhamnosus; NS, not signiﬁcant.
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Journal of PerinatologyThe number of invasive Candida infections between the three
groups was not statistically different. All the infants with
IFI had a gestational age <32 weeks and a birth weight <1500g.
The site of isolation of all the Candida species was peripheral blood
(Table 3). No statistical differences between the three groups were
observed in the duration of antimycotic treatment. In infants
affected by Candida infections, the antimycotic or antibiotic
treatment associated with probiotic supplementation
resulted in a fast clinical improvement, with fewer days of
treatment in the two probiotic groups than in the control
group (Table 2, Figure 2). The same was observed for bacterial
infections (Table 2).
The use of L. reuteri led to a signiﬁcant reduction in the
number of days of hospitalization than the L. rhamnosus and the
control groups (P<0.0001) (Table 2) (Figure 1).
In Table 2, the data of the population divided according to the
birth weight are reported; the differences between the three groups
observed in the total population were conﬁrmed only for the
newborns with a birth weight X1500g. For those with a birth
weight <1500g, the differences were signiﬁcant between the
L. reuteri and L. rhamnosus groups for the duration of parenteral
nutrition, the days to achieve the energy quotient, the days of
antibiotic treatment and the duration of hospitalization, with better
results for the former. Furthermore, newborns treated with
L. reuteri showed lesser number of days of antibiotic treatment and
lesser duration of hospitalization than the control group.
Neurological assessment
In all, 202 out of 249 newborns showed a normal neurological
assessment within the normal range of the optimal scores at the
HINE; 47 presented suboptimal scores; no statistical differences
were observed in the incidence of suboptimal scores in the groups
of infants treated with probiotics (n¼10 with L. reuteri,
n¼13 with L. rhamnosus; P>0.05). A statistically signiﬁcant
higher incidence of suboptimal scores (P<0.05) was observed in
the control group (n¼24) than in both the probiotic
groups. A total of 40 infants reported an abnormal cranial US with
no statistical differences (P>0.05) among the three groups
(Table 1).
Discussion
This is the ﬁrst study comparing two different species of probiotics;
we demonstrate their efﬁcacy in the prevention of gastrointestinal
colonization by Candida species and in reducing gastrointestinal
symptoms; furthermore, we observed a lower incidence of
neurological problems in infants supplemented with probiotics.
We selected L. reuteri ATCC 55730 and L. rhamnosus ATCC
53103 because they are the most well-documented probiotics in
terms of safety and capability to colonize the human
intestine;
16,17,25,26,31 for this reason, no fecal analysis of intestinal
colonization was conducted.
Table 2 Principal ﬁndings in the three groups of infants
Parameters L. reuteri (I) L. rhamnosus (II) Control (III) P-value <0.05
Total population <1500g >1500g
No. of newborns 83 83 83 FF F
No. of infants with gastrointestinal symptoms 3 29 36 I vs II
I vs III
NS I vs II
I vs III
No. of infants feeding hydrolyzed milk 0 7 14 I vs II
I vs III
II vs III
NS I vs II
I vs III
Days of parenteral nutrition (mean±s.d.) 6.8±5.4 13.0±10.5 13.5±11.6 I vs II
I vs III
I vs II I vs II
I vs III
Days to achieve the energy quotient
(kcal 100/kg os) (mean±s.d.)
6.8±4.1 11.3±6.8 11.3±8.1 I vs II
I vs III
I vs II I vs II
I vs III
Days of antibiotic treatment (mean±s.d.) 3.4 ±2.2 5.8±3.8 6.9±4.5 I vs II
I vs III
Iv sI I
I vs III
Iv sI I
I vs III
No. of infants with bacterial infections 0 1 5 NS NS NS
Stool fungal high colonization (CFU per g>10
4) 6 9 19 I vs III
II vs III
NS I vs III
Number of infants with mycotic infections 1 1 4 NS NS NS
Days of antimycotic treatment (mean±s.d.) 0.2±2 0.2±2 1.4±6.4 NS NS NS
Days of hospitalization (mean±s.d.) 17.8±7.9 26.9±15.7 31.3±16.3 I vs II
I vs III
Iv sI I
I vs III
Iv sI I
I vs III
Abbreviations: CFU, colony-forming unit; L. reuteri, Lactobacillus reuteri; L. rhamnosus; Lactobacillus rhamnosus; NS, not signiﬁcant.
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Journal of PerinatologyThe results of this study show a signiﬁcant reduction in
gastrointestinal colonization by Candida among the preterms
treated with probiotics, as reported by a previous study.
32
The number of invasive Candida infections between the three
groups was not statistically different even if the frequency in the
control group was higher than in the groups treated with L. reuteri
and L. rhamnosus. Wagner et al.
33 studied athymic mice with an
oral challenge of Candida and reported that fungal colonization
was attenuated in mice with a normal gut ﬂora compared with
those with germ-free microﬂora. These data highlight the fact that
the intestinal microﬂora may be as important as an intact immune
system in preventing fungal colonization.
34–37
Manzoni et al.,
32 in a prospective, randomized, blind, clinical trial
involving 80 very-low-birth-weight infants, reported that oral
administration of L. rhamnosus reduced the incidence and the
intensity of fungal enteric colonization with no associated adverse
effects. The authors suggested a fold reduction in fungal gut
colonization in newborns with a birth weight <1000g using a
combination of probiotics and drugs (ﬂuconazole in prophylaxis).
The potential mechanisms by which probiotics may modify fungal
ecology in the gut include a competitive exclusion of fungi, as well as
a reduction in their ability to colonize the enteric mucosa through
enhanced mucosal IgA responses; it could permit changes in
intestinal permeability, with an increased gut mucosal barrier against
fungi and the modiﬁcation of the host response to fungal products.
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PARENTERAL  NUTRITION
ENERGY QUOTIENT ACHIEVED
L. reuteri L. rhamnousus Control group
L. reuteri L. rhamnousus Control group
Figure 1 Days to achieve the energy quotient (kcalkg
 1) and days of parenteral
nutrition in the three groups of infants. Scatter plots show Min and Max (—),
25th centiles (m), 75th centiles (*) and median values (’).
Table 3 Characteristics of preterm infants with systemic fungal infections
Parameters L. reuteri L. rhamnosus Controls
No. of newborns 1 1 4
Gestational age (weeks) 25 30 29.5±1.8
Birth weight (g) 790 1.380 1.280±441.5
Male/female 1/0 0/1 3/1
Cesarean sections 1 1 3
Assisted ventilation (days) 3 3 3.6±0.9
Central venous catheter (days) 30 30 44±18
Antimycotic treatment (days) 16 22 40.7±16.2
Candida strains C. albicans C. albicans 2 C. albicans
1 C. parapsilosis
1 C. guillermondi
Sites of infections Blood Blood Blood
Abbreviations: C. albicans, Candida albicans; C. guillermondi, Candida guiller-
mondi; C. parapsilosis, Candida parapsilosis; L. reuteri, Lactobacillus reuteri;
L. rhamnosus; Lactobacillus rhamnosus.
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DAYS OF HOSPITALISATION
ANTIBIOTIC TREATMENT
L. reuteri L. rhamnousus Control group
L. reuteri L. rhamnousus Control group
Figure 2 Days of antibiotic treatment and hospitalization. Scatter plots
show Min and Max (—), 25th centiles (m), 75th centiles (*) and median
values (’).
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Journal of PerinatologyOur study shows the potential beneﬁcial effects of L. reuteri
supplementation on clinical and physiological variables related to
gut function, consistently higher than L. rhamnosus and control
groups. L. reuteri improves feeding tolerance, bowel habits and
gastric motility by increasing the gastric emptying rate and
reducing the fasting antral area, and then reducing episodes of
regurgitation. Different results between the two probiotics could be
due to a lower colonization of L. rhamnosus in preterm infants
with a birth weight <1500g (25%) than in those with a birth
weight between 1500 and 1999g (50%).
27 Probiotic colonization
depends on the interplay of multiple factors in the intestinal
milieu. The ﬁrst and foremost factor is the bacterial tolerance to
both acid and alkaline environments. L. reuteri is reported to be
highly resistant to the acid pH and to the antibiotic treatment
thanks to a reduced length of the parenteral nutrition and of the
use of central venosus catheter with lesser bacterial infection.
36,38
The frequent use of broad-spectrum antibiotics, in preterms
alters the intestinal milieu, favoring colonization and
infections with multiresistent bacteria and fungi.
28 Our results
show that probiotic supplementation reduces Candida colonization
in NICU newborns, leading to a reduction in the duration of
hospitalization.
Another interesting result of our study is that the control group
fed a higher percentage of hydrolyzed formula milk than did the
probiotic groups, especially the L. reuteri group, which showed an
increased food tolerance, probably due to its changes in intestinal
ﬂora, improvement in mucosal barrier and anti-inﬂammatory
properties as suggested by other authors.
22,39
Postnatal steroid has been frequently used in the management
of infants with chronic lung disease and airway edema
hypotension, but their use is not free from adverse effects as the
increased risk for the development of fungal sepsis and several
retinopaty of prematurity
40 or the increased impairment with
higher dose.
41
The neurological status of preterms with a history of sepsis was
examined in few studies, reporting that these infants had a worse
neuronal development compared to control group at 18 months of
age.
18 In a large cohort of 6093 extremely low-birth-weight infants,
Stoll et al.
42 reported the neurodevelopmental differences between
infected and uninfected infants, with an increased rate of adverse
effects, as mental and psychomotor retardation, vision and hearing
impairment and cerebral palsy, in children with infections.
Although our neurological follow-up stopped at 1 year, our results
are in accordance with the literature, as a higher incidence of poor
neurological outcomes was observed in the control group, showing
a higher frequency of Candida infections and stool colonization
compared with the probiotic groups. As in the neonatal period, a
similar neurological condition was reported (similar number of
abnormal cerebral US), we suppose that candidemia may have a
signiﬁcant role in the neurological outcomes of the control group
newborns. Therefore, our data suggest that a close neurological
follow-up is necessary for infants with a diagnosis of sepsis and
that probiotic supplementation may improve their neurological
status.
In conclusion, the use of probiotics appears to be effective in the
prevention of gastrointestinal colonization by Candida and in the
protection from mycotic infections.
Both used probiotics had good safety and did not show any
adverse reactions or side effects in preterm infants. Furthermore,
they induced an attenuation of gastrointestinal symptoms and a
more rapid weaning from the total parenteral nutrition, with a
reduction in the number of days of hospitalization.
In the groups of newborns supplemented with probiotics, we
noted fewer gastrointestinal symptoms, earlier achievement of food
tolerance, a more rapid discontinuation of parenteral nutrition and
a better neurological outcome at 1 year, than the control group.
Further studies with a larger newborn population weighing
<1000g are required to establish both the safety and the efﬁcacy
of probiotics in NICU.
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